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The prevalence and phenotypic characteristics of the 
syndrome of premature aging in women in peri- and 
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INTRODUCTION
In recent years, the premature aging syndrome 
has been widely discussed in the literature.[1-4] In 
this regard, timely detection and correction of the 
syndrome of premature aging, which is the main and 
most common form of aging of over 40–50s, gains 
its importance.[5,6] It should be noted that there are 
certain gender differences in the nature of the course 
of the disease. In men, the syndrome of premature 
aging begins earlier is associated with lifestyle and 
bad habits. Onset in women usually coincides with 
climacteric changes that are characterized not only by 
clinical symptoms but also by the addition of a number 
of diseases due to decrease of estrogen protection.[7-9] 
While the climacteric syndrome has clear clinical 
manifestations, which makes its diagnosis relatively 
simple, it is extremely early to speak of the successes 
of its timely detection and, accordingly, adequate 
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therapy. For example, until now, many specialists are 
extremely cautious about the prescription of hormone 
replacement therapy, lack of knowledge of their 
indications, and contraindications. In addition, existing 
measures to prevent premature aging are often focused 
on the elimination of its clinical manifestations without 
taking into account the need to correct its biological 
manifestations. Therefore, it is important to study the 
relationship between the phenotypic manifestations of 
premature aging in peri- and post-menopausal period, 
its genetic and molecular characteristics.
Objective of the Research
The objective of this study was to study the phenotypic 
characteristics of the syndrome of premature aging in 
women in peri- and post-menopausal period.
MATERIALS AND METHODS
To comprehensively study the parameters of the 
biological age of women in peri- and post-menopausal 
periods and identify whether they have premature 
aging syndrome, 175 women aged 45–64 years, were 
examined, mean age was 54.5 ± 2.5 years old. In this 
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case, to assess the dynamics of the premature aging, 
the patients were divided by age based on a 5-year 
interval: 45–49 years, 50–54 years, 55–59 years, and 
60–64 years.
Inclusion criteria were the passage of a planned 
routine inspection, the appearance of the complaints, 
characteristic for the perimenopausal period, and the 
absence of hormone replacement therapy for menopausal 
symptoms; exclusion criteria were the presence of 
severe or exacerbated/decompensated somatic and 
neuropsychiatric diseases, and the patient’s refusal of 
informed consent for her in-depth examination.
To identify the status characterizing the processes 
of premature aging, we conducted the following 
anthropometric examination within the framework 
of an in-depth prophylactic study: Measurement of 
body weight (in kg), measurement of blood pressure 
and calculation of pulse pressure (in mmHg), timed 
inspiratory and expiratory capacity - Stange and 
Genchi’s tests (in seconds), determination of the vital 
capacity of the lungs (spirography, in liters), a static 
balancing test according to the standard method (in 
seconds), patient questioning for identifying self-rated 
health index (on a 10-point visual analog scale, in 
points), and measurement of handgrip (torque, in kg). 
These indicators provided an opportunity to calculate 
the actual and proper biological age according to 
the method by V.P. Voitenko[10] and the aging factor 
indicating the presence of the syndrome of premature 
aging. The formula for women was used:
ABA =  1.46 + 0.42 × PP + 0.25 × W + 0.7 × SRH 
– 0.14 × SB,
Where
ABA - actual biological age,
PP - pulse pressure,
W - body weight
SRH - self-rating health
SB - static balancing.
To identify the factors that accelerate the aging process 
in women in peri- and post-menopausal periods, we 
performed the following studies: 1) Instrumental 
examination - screening densitometry of the bones of 
the hands (the force index F was used, expressed in 
%: F = hand strength (daN) × 0.98/body weight (kg) 
× 100); 2) laboratory tests - determination of HOMA 
IR score, levels of serum proinflammatory cytokines 
(tumor necrosis factor α [TNF-α], interleukins 1 
[IL-1] and interleukins 6 [IL-6] [in pg/ml]), and lipid 
metabolism - triglyceride, total cholesterol, low-
density lipoprotein, and high-density lipoprotein in 
the blood serum (mmol/l).
An additional anthropometric examination was 
performed to determine body composition. For this 
purpose, we calculated the following parameters: Fat 
mass according to the Mateika formula (2009) (in kg), 
fat fraction (in %), lean mass (in kg), and subcutaneous 
and visceral fat (in cm2).
To calculate these indicators, we used the following 
formulas:
• Fat mass = total fat (kg) × average value of 
subcutaneous fat (in millimeters) × body surface 
area (in square centimeters) × 0.13;
• Average value of subcutaneous fat = total thickness 
of skin-fat folds (in millimeters) on the shoulder in 
front and behind, forearm, back, abdomen, thigh, 
lower leg, and chest/14;
• Percentage of fat = total fat (kg) × 100/body weight 
(kg);
• Muscle mass = height (in centimeters) × mean value 
of the shoulder, forearms, thighs, and drumsticks 
radii (without the subcutaneous tissue and skin) 
(in centimeters) × 6.5, wherein the mean value of 
the radii defined by the following formula: Sum 
of the four circumferences/25.12 - sum of five fat 
folds/100.
Calculation of the above-described anthropometric 
indicators allowed us to diagnose sarcopenic obesity 
as a factor of the syndrome of accelerated aging. To 
identify factors that determine the acceleration of the 
aging process in women in peri- and post-menopausal 
periods, we studied in selected groups the prevalence 
of cardiovascular and metabolic diseases, as well as the 
severity of the main manifestations of the climacteric 
syndrome (fever sensation, sweating, headache, blood 
pressure variation, vasomotor rhinitis, dryness of the 
mucous membranes of the genital tract, and anxiety-
depressive syndrome) on a 10-point visual analog scale.
RESULTS AND DISCUSSION
An in-depth anthropometric study used to calculate 
the biological age by Voitenko’s method found that 
most of the calculated parameters, with the exception 
of body weight, which tended to increase, statistically 
significantly worsened as age increased. The summary 
characteristic of the obtained anthropometric data, 
necessary for calculating the biological age, is 
presented in Table 1.
Using these indicators, we found that the dynamics 
of the index of the actual biological age/proper 
biological age (aging factor) in the studied age 
groups was as follows: 45–49 years - 1.0±0.02, 
50–54 years - 1.3±0.01, 55–59 years old - 1.4±0.01, 
and 60 years and over - 1.6±0.02; P < 0.05. That is, 
at a normal mean biological age in the age group of 
45–49 years, starting from the age of 50, the biological 
age advanced the passport age, that is, the syndrome 
of premature aging developed.
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Its actual prevalence in the studied groups was as 
follows: 45–49 years - 5 patients (12.2%), 50–54 
years - 32 patients (71.1%), 55–59 years - 38 patients 
(86.4%), and 60 years and older - 41 patients, which 
was 91.1% [Table 2].
The study of the factors associated with the process of 
premature aging in women in perimenopausal period 
resulted in the following data.
The patients in the age group of 60 years and older 
had a subclinical development of osteopenia at 
normal indicator of bone mineral density (T-score); in 
the younger age groups: 45–49 years - −0.9 ± 0.08, 
50–54 years - −0.9±0.03, 55–59 years - −0.8 ± 0.07, 
and 60 years and older - −1.5 ± 0.09 (strong positive 
correlation with premature aging syndrome, r=+0.90; 
P < 0.05).
The study revealed that the average age of the onset 
of menopause was 48.7 ± 1.5 years (47–51 years), 
with the first menopausal disorders occurring the age 
of 46.5 ± 1.2 years (45–47 years). The comparison of 
clinical and laboratory data with biological markers of 
the processes of premature aging showed that against 
the background of menopausal disorders there was 
an age-dependent deterioration of the lipid profile 
(a strong positive correlation with the syndrome of 
premature aging, r = +0.92; P < 0.05), the formation 
of chronic immune inflammation (a strong positive 
correlation with the syndrome of premature aging, 
r = +0.88; P < 0.05), and an increase in the insulin 
resistance index (a strong positive correlation with the 
syndrome of premature aging, r = +0.93; P < 0.05). 
At the age of 50–54 years, worsening of pathological 
processes occurred and continued exacerbating at the 
age of 55–59 years, with their stabilization at the age 
of 60 years and older [Table 3].
The correlation analysis showed that the HOMA score 
in the over 50s significantly exceeded the normal 
values and significantly increased during the aging 
process - 50–54 years - 1.9 ± 0.2, 55–59 years - 2.1 ± 
0.1, and 60 years and older - 2.4 ± 0.2, which indicates 
a strong positive correlation with premature aging 
syndrome, r = +0.9; P < 0.05. Triglyceride values did not 
exceed their normal range, but statistically significantly 
increased with age, the total cholesterol level exceeded 
the normal values at the age of 60 years and older - 6.2 
± 1.0 mmol/l, which had a strong positive correlation 
with the syndrome of premature aging, r=+0.9; P < 0.05.
We found that as the age increased, after the onset 
of menopause, there were statistically significant 
changes and anthropometric markers characterizing 
the processes of premature aging. Thus, there was a 
progressive significant decrease in the force index 
F from 56.8 ± 1.2% in women aged 45–49 years to 
51.3 ± 0.9% at the age of 50–54 years, 46.2 ± 1.0% 
at the age of 55–59 years, and 42.1 ± 1.1% at the age 
of 60 years and older (P < 0.05 compared with the 
related age groups). A decrease in muscle strength was 
accompanied by a significant (P < 0.05) increase in 
the body mass index, the proportion of fat, and the 
area of subcutaneous and visceral fat, indicating the 
development of sarcopenic obesity [Table 4].
The correlation analysis showed a strong positive 
correlation of sarcopenic obesity with a syndrome of 
premature aging (r = +0.86, P < 0.05).
Table 1: Dynamics of calculated indicators of biological age by V.P. Voitenko in patients in peri‑ and 
post-menopausal period and their chronicity
Data required for the calculation 
of biological age
Age group (years)
45–49 (n=41) 50–54 (n=45) 55–59 (n=44) 60 and over (n=45)
Body weight (kg) 71.4±3.4 73.1±2.8 75.4±2.9 79.5±4.1
Systolic blood pressure, mmHg 139.4±5.7 141.5±4.1 159.1±3.2* 165.4±3.1*
Diastolic blood pressure, mmHg 89.3±1.2 91,7±1.1 94.3±2.1* 97.1±2.4*
Pulse pressure, mmHg 50.1±1.5 49.8±1.4 64.8±2.1* 68.3±2.0*
Stange’s test (s) 43.4±1.2 42.8±1.1 40.1±0.9* 37.5±0.8*
Genchi’s test (s) 38.3±1.1 37.0±0.8 36.1±0.7 35.0±0.5*
Vital capacity (L) 2.6±0.1 2.5±0.2* 2.4±0.1* 2.3±0.1*
Static balancing (s) 51.3±1.1 50.4±1.0 48.3±0.8* 45.2±0.9*
Self-rating health 8.1±0.2 8.0±0.1 7.4±0.3* 7.0±0.4*
*P<0.05 compared with the previous age group
Table 2: Age‑specific features of the prevalence of the syndrome of premature aging in women in peri‑ and 
post‑menopausal period (by Voitenko’s method)
Indicator Age group (years)
45–49 (n=41) 50–54 (n=45) 55–59 (n=44) 60 and over (n=45)
abs. (%) abs. (%) abs. (%) abs. (%)
Prevalence 5 (12.2) 32 (71.1) 38 (86.4) 41 (91.1)
Average aging factor (normally equal to 1.0) 1.0±0.02 1.3±0.01* 1.4±0.01* 1.6±0.02*
* P<0.05 compared with the previous age group. Abs: Absorbance
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Summary
The development of the syndrome of premature 
aging is observed in women in peri- and post-
menopausal periods since the age of 50 years, and 
its prevalence increases with age - at 50–54 years 
it is reported in 71.1% of the observed patients, at 
the age of 55–59 years - in 86.4%, and at the age 
of 60–64 years - in 91.1% of women. Against the 
menopausal changes, starting at the age of 50 years, 
women develop a syndrome of premature aging, 
which is manifested by acceleration of the aging 
rate at the age of 50–54 years by 1.3, at the age 
of 55–59 years by - 1.4, and at the age of 60 and 
older - by 1.6 times.
Neurohumoral mechanisms described in premature 
aging in post-menopausal period and associated with 
a cytokine tension increase in the level of serum 
pro-inflammatory cytokines such as TNF-a and 
interleukins 1 and 6.
Premature aging in peri- and post-menopausal period 
is accompanied by a significant decrease in the force 
index from 56.8% in women aged 45–49 to 51.3% at 
the age of 50–54, 46.2% at the age of 55–59 years, 
and 42.1% at the age of 60 years and older (P < 0.05), 
with a simultaneously observed significant increase 
in the body mass index, the proportion of fat and the 
area of subcutaneous and visceral fat, indicating the 
formation of sarcopenic obesity.
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Table 3: Dynamics of clinical and laboratory indicators in patients in peri‑ and post‑menopausal period
Indicator Age group (years)
45–49 (n=41) 50–54 (n=45) 55–59 (n=44) 60 and over (n=45)
HOMA score 1.7±0.4 1.9±0.02* 2.1±0.01* 2.4±0.02*
TNF-α, pg/ml 5.1±0.02 5.5±0.03* 5.9±0.01* 6.7±0.04*
IL-1, pg/ml 2.1±0.01 2.4±0.02* 2.7±0.01* 3.1±0.02*
IL-6, pg/ml 2.7±0.02 3.1±0.01* 3.5±0.02* 3.9±0.01*
Triglycerides, mol/l 1.2±0.01 1.4±0.02* 1.5±0.1 1.7±0.02*
Total cholesterol, mol/l 4.7±0.12 5.2±0.13* 5.7±0.14* 6.2±0.04*
LDL 1.01±0.02 1.04±0.01* 1.06±0.02* 1.07±0.01
HDL 1.27±0.06 1.26±0.01 1.0±0.01* 0.84±0.02*
*P<0.05 compared with the previous age group, TNF-α: Tumor necrosis factor, IL-6: Interleukin 6, IL-1: Interleukin 1
Table 4: Dynamics of in‑depth anthropometric data on body composition in women in perimenopausal period
Indicator Age group (years)
45–49 (n=41) 50–54 (n=45) 55–59 (n=44) 60 and over (n=45)
Fat mass (kg) 18.7±0.9 22.1±0.5* 24.8±0.5* 27.1±0.7*
Fat proportion (%) 30.5±0.02 32.1±0.03* 33.9±0.04* 35.8±0.03*
Subcutaneous fat (cm2) 212.2±5.1 228.4±1.3* 249.3±2.5* 261.1±2.2*
Visceral fat (cm2) 45.1±0.4 51.5±1.3* 57.8±2.1* 65.9±2.9*
Body mass index 23.1±1.2 27.4±0.8* 29.1±0.5* 33.1±0.7*
*P<0.05 compared with the previous age group
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